ibritumomab
Sign in to saveAlso known as Ig gamma-2A chain C region, membrane-bound form, radiolabeled murine anti-CD20
radioimmunotherapy treatment
Medication
- Active ingredients
- ibritumomab tiuxetan
Sources: openFDA · RxNorm (NLM). Not medical advice.
Clinical Trials
77 registered- PHASE2COMPLETEDRituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell LymphomaMemorial Sloan Kettering Cancer Center · NCT00058422
- NACOMPLETEDRadioimmunotherapy With 90Y Zevalin for Orbital LymphomaM.D. Anderson Cancer Center · NCT00387023
- PHASE2UNKNOWNStudy Combining Zevalin With High-Dose Chemotherapy Prior to Autologous StemCell Transplant in Patients With Relapsed, Refractory, or Transformed Non-Hodgkin's LymphomaMcGill University · NCT00438581
- PHASE2COMPLETEDAllogenic Stem Cell Transplantation (SCT) With Non-myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL)Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea · NCT00644371
- PHASE2COMPLETEDRituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell LymphomaNational Cancer Institute (NCI) · NCT00070447
- PHASE2COMPLETEDSafety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02)CABYC · NCT00505232